557 related articles for article (PubMed ID: 14981513)
1. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.
Harrington EA; Bebbington D; Moore J; Rasmussen RK; Ajose-Adeogun AO; Nakayama T; Graham JA; Demur C; Hercend T; Diu-Hercend A; Su M; Golec JM; Miller KM
Nat Med; 2004 Mar; 10(3):262-7. PubMed ID: 14981513
[TBL] [Abstract][Full Text] [Related]
2. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
Jani JP; Arcari J; Bernardo V; Bhattacharya SK; Briere D; Cohen BD; Coleman K; Christensen JG; Emerson EO; Jakowski A; Hook K; Los G; Moyer JD; Pruimboom-Brees I; Pustilnik L; Rossi AM; Steyn SJ; Su C; Tsaparikos K; Wishka D; Yoon K; Jakubczak JL
Mol Cancer Ther; 2010 Apr; 9(4):883-94. PubMed ID: 20354118
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.
Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q
J Transl Med; 2011 May; 9():74. PubMed ID: 21600017
[TBL] [Abstract][Full Text] [Related]
4. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
Pan C; Yan M; Yao J; Xu J; Long Z; Huang H; Liu Q
Oral Oncol; 2008 Jul; 44(7):639-45. PubMed ID: 17996488
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.
Chan F; Sun C; Perumal M; Nguyen QD; Bavetsias V; McDonald E; Martins V; Wilsher NE; Raynaud FI; Valenti M; Eccles S; Te Poele R; Workman P; Aboagye EO; Linardopoulos S
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3147-57. PubMed ID: 18089709
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
9. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
Tyler RK; Shpiro N; Marquez R; Eyers PA
Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
Anderson K; Lai Z; McDonald OB; Stuart JD; Nartey EN; Hardwicke MA; Newlander K; Dhanak D; Adams J; Patrick D; Copeland RA; Tummino PJ; Yang J
Biochem J; 2009 May; 420(2):259-65. PubMed ID: 19284385
[TBL] [Abstract][Full Text] [Related]
11. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
12. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
Lin ZZ; Hsu HC; Hsu CH; Yeh PY; Huang CY; Huang YF; Chen TJ; Kuo SH; Hsu C; Hu FC; Jeng YM; Chung Y; Cheng AL
J Hepatol; 2009 Mar; 50(3):518-27. PubMed ID: 19155085
[TBL] [Abstract][Full Text] [Related]
13. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.
Ulisse S; Arlot-Bonnemains Y; Baldini E; Morrone S; Carocci S; Di Luigi L; D'Armiento M
J Endocrinol; 2010 Feb; 204(2):135-42. PubMed ID: 19889886
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
McLaughlin J; Markovtsov V; Li H; Wong S; Gelman M; Zhu Y; Franci C; Lang D; Pali E; Lasaga J; Low C; Zhao F; Chang B; Gururaja TL; Xu W; Baluom M; Sweeny D; Carroll D; Sran A; Thota S; Parmer M; Romane A; Clemens G; Grossbard E; Qu K; Jenkins Y; Kinoshita T; Taylor V; Holland SJ; Argade A; Singh R; Pine P; Payan DG; Hitoshi Y
J Cancer Res Clin Oncol; 2010 Jan; 136(1):99-113. PubMed ID: 19609559
[TBL] [Abstract][Full Text] [Related]
16. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509
[TBL] [Abstract][Full Text] [Related]
17. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Gizatullin F; Yao Y; Kung V; Harding MW; Loda M; Shapiro GI
Cancer Res; 2006 Aug; 66(15):7668-77. PubMed ID: 16885368
[TBL] [Abstract][Full Text] [Related]
18. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
19. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma.
Wan XB; Fan XJ; Chen MY; Xu J; Long ZJ; Hua YJ; Ji H; Liu L; Hong MH; Zeng YX; Liu Q
Cancer Biol Ther; 2009 Aug; 8(15):1500-6. PubMed ID: 19502819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
